Gain Therapeutics (GANX) Total Non-Current Liabilities (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Total Non-Current Liabilities of $844913.0 for Q1 2026, up 3.55% year-over-year from $815921.0 in Q1 2025, and down 6.31% quarter-over-quarter from $901831.0 in Q4 2025.
Gain Therapeutics (GANX) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Gain Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $844913.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 3.55% year-over-year to $844913.0; the TTM figure through Mar 2026 stood at $844913.0 (up 3.55% YoY), while the FY2025 annual figure was $901831.0, up 3.3% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $844913.0, down from $901831.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.6 million in Q2 2023, with the low at $815921.0 in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $940886.0 (2025), against an average of $1.1 million.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities climbed 24.27% in 2022, then slumped 43.76% in 2024.
- Gain Therapeutics' Total Non-Current Liabilities stood at $1.1 million in 2022, then dropped by 1.23% to $1.1 million in 2023, then slipped by 19.25% to $872989.0 in 2024, then advanced by 3.3% to $901831.0 in 2025, then declined by 6.31% to $844913.0 in 2026.
- Business Quant data shows GANX's Total Non-Current Liabilities at $844913.0 in Q1 2026, $901831.0 in Q4 2025, and $891648.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 696,043.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 696,043.00 |
| Mar 31, 2026 | 844,913.00 |
| Dec 31, 2025 | 901,831.00 |
| Sep 30, 2025 | 891,648.00 |
| Jun 30, 2025 | 940,886.00 |
| Mar 31, 2025 | 815,921.00 |
| Dec 31, 2024 | 872,989.00 |
| Sep 30, 2024 | 861,487.00 |
| Jun 30, 2024 | 888,465.00 |
| Mar 31, 2024 | 930,987.00 |
| Dec 31, 2023 | 1.08 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 1.58 Mn |
| Mar 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 1.46 Mn |
| Mar 31, 2022 | 1.55 Mn |
| Dec 31, 2021 | 1.61 Mn |
| Sep 30, 2021 | 1.44 Mn |